Iofina shares climb as record iodine output lifts profits outlook

Iofina produced a record 743.2 tonnes of crystalline iodine in 2025 (up 17.2% y/y) with Q4 output of 221.8t, and says 2025 revenues will exceed $65m and EBITDA will be above $11m; net cash rose to $5.2m from $2.9m a year earlier. High spot iodine prices (above $70/kg through 2025) and strong second-half sales underpinned the beat and the board expects 325–355t of production in H1 2026; the company is building a Permian Basin plant (50,000 bpd brine capacity) due in H2 2026 expected to add ~170–220t annually. These operational and financial upgrades support a positive outlook for the shares and investor positioning in the stock.

Analysis

Market structure: Iofina’s +17.2% production to 743.2 t and guidance (revenues >$65m, EBITDA >$11m) plus a spot iodine price >$70/kg materially improves its unit economics and short-term pricing power. The Permian plant (50k bbl/day → 170–220 tpa) coming H2‑2026 is a capacity step-change that can shift share toward integrated brine-extractors at the expense of smaller producers and traders, tightening the specialty iodine supply curve if demand persists.

Risk assessment: Key tail-risks are regulatory/permit delays on brine extraction, a sharp oilfield activity slowdown (reducing brine volumes), or an iodine price collapse from alternative supply or recycling; each could wipe out 30–60% of equity value. Time horizons: immediate (days) – sentiment pop; short (weeks–months) – H1 2026 output 325–355 t and quarterly sales; long (H2‑2026+) – plant commissioning and capex execution risk. Hidden dependency: revenues indexed to USD spot iodine prices while shares trade in GBP (FX can amplify moves).

Trade implications: Direct play – establish a 2–3% long position in IOF.L (AIM:IOF) at ≤30p, target 45–50p in 6–12 months, stop-loss 18–20p; US investors use OTC: IOFNF equivalent. Options – if liquid, buy 9–12 month call spread (e.g., 30p/45p) to cap premium; alternatively buy 12‑month protective puts at 20p to limit downside. Pair trade – long IOF.L vs short ICL (NYSE:ICL) or a diversified materials ETF (e.g., XLB) sized to net out broader commodity beta and isolate iodine-specific upside.

Contrarian angles: Consensus may underprice operational/capex execution risk — market assumes H2‑2026 plant on time and sustained >$70/kg prices; a 3–6 month commissioning slip or price reversion to <$50/kg would be material. The current 6% pop likely underreacts to H2 upside but overreacts if early 2026 winter disruptions persist; require 1–2 quarterly confirmations (by May–Aug 2026) before scaling beyond initial size.

Key Decisions for Investors

• Establish a 2–3% long position in IOF.L (AIM:IOF) at or below 30p, target 45–50p within 6–12 months, set a hard stop-loss at 18–20p to limit downside from operational/regulatory shocks.
• US investors: buy equivalent exposure via OTC: IOFNF sized to match the 2–3% allocation; prefer direct equity due to likely option illiquidity on AIM/OTC.
• Implement a defined‑risk options play if available: buy a 9–12 month IOF call spread (e.g., long 30p / short 45p) sized for 1% portfolio risk, or buy 12‑month protective puts struck at ~20p to limit tail losses if holding shares.
• Enter a relative‑value pair: long IOF.L vs short ICL (NYSE:ICL) or short XLB sized to neutralize broad materials exposure — reweight after H1 2026 production release (expected by May 2026) to isolate iodine price/operational delta.
• Monitor three binary catalysts before increasing position: (1) H1 2026 production report (window Jan–May 2026), (2) Permian plant commissioning update by Aug–Dec 2026, (3) sustained iodine spot >$60/kg for 60+ days; if any fail, reduce position by 50% within 5 trading days.